Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.

The Strategy

• Develop drugs to Phase II
• Partner with the pharma leader in the field

Therapeutic Focus

• CNS (Central Nervous System) disorders
• Metabolic diseases

Target Product Profile

• Disease-modifying, slowing disease progression
• Large age-related disease indications with unmet medical needs